Michelle D Po
Overview
Explore the profile of Michelle D Po including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arnold V, Lopez F, Childress A, Po M, Uchida C, Cuthbertson L, et al.
J Atten Disord
. 2024 Apr;
28(8):1186-1197.
PMID: 38600754
Objective: DR/ER-MPH (formerly HLD200) is an evening-dosed delayed-release and extended-release methylphenidate approved for the treatment of ADHD in patients ≥6 years. analyses of two pivotal Phase 3 trials: HLD200-107 (NCT02493777)...
2.
Katzman M, Otcheretko V, Po M, Uchida C, Incledon B
Clin Ther
. 2023 Sep;
45(12):1212-1221.
PMID: 37770309
Purpose: Delayed-release/extended-release methylphenidate (DR/ER-MPH) (formerly HLD200) is an evening-dosed agent used for the treatment of attention-deficit/hyperactivity disorder. Postmarketing surveillance data from approximately 74,000 patients exposed to DR/ER-MPH (up to June...
3.
Po M, Gomeni R, Incledon B
Innov Clin Neurosci
. 2022 Oct;
19(7-9):32-37.
PMID: 36204174
Objective: Extended-release methylphenidate (ER-MPH) formulations used to treat attention deficit hyperactivity disorder (ADHD) have complex pharmacokinetic (PK) profiles, resulting from differing ratios of immediate-release and extended-release components and/or their site...
4.
Childress A, Cutler A, Po M, DeSousa N, Warrington L, Sallee F, et al.
J Clin Psychiatry
. 2021 Jun;
82(4).
PMID: 34166587
Delayed-release and extended-release methylphenidate (DR/ER-MPH), the first stimulant predicted to be absorbed primarily in the colon, demonstrated significant improvements in attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment from awakening until...
5.
Childress A, Uchida C, Po M, DeSousa N, Incledon B
Clin Ther
. 2020 Nov;
42(12):2332-2340.
PMID: 33168234
Purpose: HLD200 is the first evening-dosed, delayed-release and extended-release methylphenidate (DR/ER-MPH) designed to delay initial release of MPH and provide treatment effects throughout the day and into the evening for...
6.
Faraone S, Po M, Komolova M, Cortese S
J Clin Psychiatry
. 2019 May;
80(3).
PMID: 31090281
Objective: Sleep disturbances are a feature of attention-deficit/hyperactivity disorder (ADHD) and an adverse event (AE) of methylphenidate treatment. The authors sought to clarify methylphenidate-associated sleep problems and how studies are...
7.
Liu T, Gobburu J, Po M, McLean A, DeSousa N, Sallee F, et al.
J Child Adolesc Psychopharmacol
. 2019 Feb;
29(3):181-191.
PMID: 30810347
Objectives: HLD200, an oral, once-daily, evening-dosed, delayed-release, and extended-release methylphenidate (DR/ER-MPH), was designed to provide efficacy from the early morning, throughout the day, and into the evening to individuals with...
8.
Gao S, Xie L, Kawano T, Po M, Pirri J, Guan S, et al.
Nat Commun
. 2015 May;
6:7191.
PMID: 25995025
No abstract available.
9.
Gao S, Xie L, Kawano T, Po M, Guan S, Zhen M, et al.
Nat Commun
. 2015 Feb;
6:6323.
PMID: 25716181
Persistent neural activity, a sustained circuit output that outlasts the stimuli, underlies short-term or working memory, as well as various mental representations. Molecular mechanisms that underlie persistent activity are not...
10.
Tildesley H, Po M, Ross S
Med Clin North Am
. 2014 Dec;
99(1):17-33.
PMID: 25456641
Internet blood glucose monitoring systems (IBGMS) are associated with improved glycemic control in patients with type 2 diabetes (T2D) who are pharmacologically managed, using oral agents or insulin. IBGMS improves...